Cost effectiveness of pharmacogenetic testing for drugs with clinical pharmacogenetics implementation consortium (CPIC) guidelines: a systematic review
SA Morris, AT Alsaidi, A Verbyla, A Cruz… - Clinical …, 2022 - Wiley Online Library
The objective of this study was to evaluate the evidence on cost‐effectiveness of
pharmacogenetic (PGx)–guided treatment for drugs with Clinical Pharmacogenetics …
pharmacogenetic (PGx)–guided treatment for drugs with Clinical Pharmacogenetics …
[HTML][HTML] The burden of liver disease in Europe: a review of available epidemiological data
M Blachier, H Leleu, M Peck-Radosavljevic… - Journal of …, 2013 - Elsevier
To survey the burden of liver disease in Europe and its causes 260 epidemiological studies
published in the last five years were reviewed. The incidence and prevalence of cirrhosis …
published in the last five years were reviewed. The incidence and prevalence of cirrhosis …
[PDF][PDF] Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale‐up in the age of direct‐acting antivirals
NK Martin, P Vickerman, J Grebely, M Hellard… - …, 2013 - Wiley Online Library
Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs
(PWID) cannot be achieved by harm reduction interventions such as needle exchange and …
(PWID) cannot be achieved by harm reduction interventions such as needle exchange and …
Current and future therapies for hepatitis C virus infection
Current and Future Therapies for Hepatitis C Virus Infection | New England Journal of Medicine
Skip to main content The New England Journal of Medicine homepage Advanced Search …
Skip to main content The New England Journal of Medicine homepage Advanced Search …
[图书][B] Cost-effectiveness in health and medicine
PJ Neumann, GD Sanders, LB Russell, JE Siegel… - 2016 - books.google.com
A COMPLETE UPDATE AND REVISION OF THE CLASSIC TEXT" At last, a manual of
operations for comparing the cost-effectiveness of a preventive service with a treatment …
operations for comparing the cost-effectiveness of a preventive service with a treatment …
Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and …
NK Martin, M Hickman, SJ Hutchinson… - Clinical Infectious …, 2013 - academic.oup.com
Background. Interventions such as opiate substitution therapy (OST) and high-coverage
needle and syringe programs (HCNSP) cannot substantially reduce hepatitis C virus (HCV) …
needle and syringe programs (HCNSP) cannot substantially reduce hepatitis C virus (HCV) …
Global control of hepatitis C: where challenge meets opportunity
DL Thomas - Nature medicine, 2013 - nature.com
We are entering an important new chapter in the story of hepatitis C virus (HCV) infection.
There are clear challenges and opportunities. On the one hand, new HCV infections are still …
There are clear challenges and opportunities. On the one hand, new HCV infections are still …
Cost-effectiveness of novel regimens for the treatment of hepatitis C virus
M Najafzadeh, K Andersson, WH Shrank… - Annals of internal …, 2015 - acpjournals.org
Background: New regimens for hepatitis C virus (HCV) have shorter treatment durations and
increased rates of sustained virologic response compared with existing therapies but are …
increased rates of sustained virologic response compared with existing therapies but are …
Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits
J Smith-Palmer, K Cerri, W Valentine - BMC infectious diseases, 2015 - Springer
Background The goal of chronic hepatitis C treatment is to remove the virus to avoid
progression of HCV-related disease. Sustained virologic response (SVR) is the most widely …
progression of HCV-related disease. Sustained virologic response (SVR) is the most widely …
Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population
HS Chahal, EA Marseille, JA Tice… - JAMA internal …, 2016 - jamanetwork.com
Importance Novel treatments for hepatitis C virus (HCV) infection are highly efficacious but
costly. Thus, many insurers cover therapy only in advanced fibrosis stages. The added …
costly. Thus, many insurers cover therapy only in advanced fibrosis stages. The added …